Mr. Roy Golan has over 20 years of experience in the Biotech and the Pharmaceuticals industries, across a range of roles and companies.
Up to June 2024, Mr. Golan served as the CFO of Ayala Pharmaceuticals Inc. (OTCQX: ADXS), a clinical-stage oncology company, following its merger with BioSight Ltd., a private pharmaceutical company developing innovative therapeutics for haematological malignancies and disorders, in October 2023, which he led. After the merger, he played a major role in the Asset deal between Ayala Pharmaceuticals Inc. and Immunome (Nasdaq: IMNM) until it closed in March 2024.
In 2019, Mr. Golan was appointed as Executive VP and CFO of BioSight Ltd., a role he held until June 2024.
Prior to his tenure at BioSight, From 2018 to 2019, Mr. Golan served as President and CFO of Exalenz Bioscience Ltd. (TASE: EXEN), a Tel Aviv Stock Exchange listed global, commercial-stage diagnostics company which developed its BreathID® technology platform to improve patient care by providing breath-based tests in the fields of gastroenterology and hepatology and was later acquired by Meridian Bioscience, Inc. (NASDAQ: VIVO).
From 2015 to 2018, Mr. Golan served as the CFO of NeuroDerm (NASDAQ: NDRM), a Nasdaq listed clinical-stage pharmaceutical company developing next-generation drug-device combinations for central nervous system disorders, through its initial public offering, several follow-on offerings and up to its acquisition by Mitsubishi Tanabe Pharma Group Company. Prior, he served as their VP Finance.
Mr. Golan holds an LLM from Bar Ilan University as well as a BA from The College of Management and is also a licensed CPA.
